Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-04T21:05:03.875Z Has data issue: false hasContentIssue false

Long-Term Safety and Effectiveness of Lurasidone in Adolescents and Young Adults With Schizophrenia: Pooled Post-hoc Analyses of Two 12-month Extension Studies

Published online by Cambridge University Press:  14 April 2023

Fabrizio Calisti
Affiliation:
Angelini RR&D (Regulatory, Research, & Development) - Angelini Pharma S.p.A., Viale Amelia, 70 - 00181 Rome, Italy
Michael Tocco
Affiliation:
Sunovion Pharmaceuticals Inc, Teaneck, NJ, and Marlborough, MA, USA
Yongcai Mao
Affiliation:
Sunovion Pharmaceuticals Inc, Teaneck, NJ, and Marlborough, MA, USA
Andrei Pikalov
Affiliation:
Sunovion Pharmaceuticals Inc, Teaneck, NJ, and Marlborough, MA, USA
Robert Goldman
Affiliation:
Sunovion Pharmaceuticals Inc, Teaneck, NJ, and Marlborough, MA, USA
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Earlier onset of schizophrenia, which occurs more commonly in males, is characterized by greater illness severity, chronicity, and functional impairment with a less favorable prognosis than later-onset schizophrenia. The aim of this pooled analysis was to evaluate the long-term safety and effectiveness of lurasidone in the treatment of schizophrenia in adolescents (13–17 years) and young adults (18–25 years).

Methods

The 2 pooled studies used similar designs and outcome measures. Patients (13–25 years) with schizophrenia completed an initial double-blind 6-week trial of lurasidone (40 and 80 mg/d), and (80 and 160 mg/d) in the young adult trial. In the open-label long-term trials, adolescent patients were treated with 20-80 mg/d of lurasidone, and adults were treated with 40–160 mg/d of lurasidone. Efficacy was evaluated based on the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression-Severity Scale (CGI-S).

Results

The safety population consisted of 306 patients (mean age, 16.2 years; 208 patients (68.0%) who completed 12 months of treatment; 8.2% discontinued by 12 months due to an adverse event. Mean (SD) change in the PANSS total score from extension Baseline to Months 6 and 12 was -11.8 (13.9) and -15.3 (15.0), respectively (OC); and mean (SD) change in the CGI-S score was -0.8 (1.0) and -1.0 (1.1), respectively (OC). The most frequent adverse events were headache (17.6%), anxiety (11.4%), schizophrenia (9.8%), and nausea (9.8). No clinically meaningful changes were observed in weight, metabolic parameters, or prolactin.

Conclusions

In adolescents and young adults with schizophrenia, treatment with lurasidone was generally well-tolerated and effective. Long-term treatment was associated with continued reduction in symptoms of schizophrenia. Long-term treatment was associated with minimal effects on weight, metabolic parameters, and prolactin.

Funding

Angelini Pharma S.p.A. and Sunovion Pharmaceuticals Inc.

Type
Abstracts
Copyright
© The Author(s), 2023. Published by Cambridge University Press